Antiva raises $16M; RegeneRx takes dry eye gene therapy into PhII;

@FierceBiotech: Scripps team finds a drug that fights addiction by eliminating memories. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: What's + PhII data from a small allergy study worth? Aimmune bags $160M IPO as the market continues to embrace bio. Article | Follow @JohnCFierce

@DamianFierce: "IPO (n.): An acronym for 'initial public offering' that neglects to mention the taking." More | Follow @DamianFierce

> Menlo Park, CA-based Antiva Therapeutics raised $16 million in a Series B round led by Canaan Partners and Sofinnova. The money is earmarked for an early-stage study of ABI-1968 for HPV infections. Release

> Gene therapy outfit RegeneRx Biopharmaceuticals is plotting to launch a Phase II trial of its treatment for dry eye in the U.S. next month following positive feedback from the FDA, the company said. More

> Amgen ($AMGN) has signed a deal with Indian drug giant Dr. Reddy's Laboratories to get its antibodies into the country. News

Medical Device News

@FierceMedDev: DNAnexus teams up with FDA for Precision Medicine cloud-based genomics platform. More from FierceDiagnostics | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Intuitive awards grants to support training of its da Vinci robot using virtual reality. Article | Follow @VarunSaxena2

@EmilyWFierce: A little news on CEO compensation. More from the WSJ | Follow @EmilyWFierce

> Global tech organization reveals new system for blood glucose monitoring devices. Story

> Medtronic recalls CoreValve TAVR component due to presence of particulate matter. News

> Miniature surgical robot startup gets $11M to assess feasibility in colon resection. Article

Pharma News

@FiercePharma: ICYMI yesterday: FDA updates label for Novartis' MS pill Gilenya after reports of brain infection. Article | Follow @FiercePharma

@EricPFierce: Aprecia is building $25M plant where it will do 3D printing of drugs. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: Perrigo CEO: Think Mylan's buyout will come easily? Think again. More | Follow @CarlyHFierce

> British watchdog cracks down on Pfizer for huge price hikes on epilepsy drug. Story

> Novo Nordisk beats in Q2 even as U.S. pricing pressures bite. Article

Vaccines News

> U.K's Prokarium scores $585,000 for oral chlamydia vaccine. Report

> State vaccination laws impact outbreak rates, study finds. Item

> Merck Ebola vaccine posts 100% efficacy in PhIII. More

> Novavax reports PhII success for quadrivalent seasonal flu vax. Story

> CSL completes purchase of Novartis' flu vaccine business. Article

CRO News

> Quintiles' $950M IPO keeps on giving for PE backers. Report

> Icon gets in on the ground floor with a Novartis-backed biotech upstart. More

> Patheon signs up to manufacture Flexion's lead drug. Item

> Parexel returns to growth after a shaky quarter. Story

> INC raises its 2015 expectations after another strong quarter. Article

Pharma Manufacturing News

> India, mad over EU ban on drugs, postpones trade talks. Item

> AMRI's expansion binge pays off for CMO. Story

> FDA warning letter smacks Indian lab for repeated shortcomings. More

> French regulator found 30 cases of mold contamination in biotech plant. Report

> GSK moves foward in Bangalore with new Indian plant. Article

Pharma Asia News

> India defers EU trade talks as ban on GVK-tested drugs rankles. Item

> China-focused Mabtech licenses four mAB candidates to Sorrento. More

> BeiGene receives first China trial approval nod for BGB-283. Story

> GSK rehires former China government affairs director Shi. Report

> AstraZeneca stands out again in China, hails AZD9291 in Japan. Article

Suggested Articles

In this week's EuroBiotech Report, GSK, Immatics strike cell therapy deal, Vifor buys priority review voucher and PharmaMar gets PDUFA date.

In our EuroBiotech roundup this week, U.K. creates life science zones, Genmab to ramp up R&D spending and Pfizer backs cancer biotech. 

Spruce Biosciences raised $88 million from the likes of Abingworth and Omega Funds to take the drug to the next level: a late-stage study in adults.